Just In
- 16 hrs ago Heeramandi Screening: Alia Bhatt, Ananya Panday, Rashmika Mandanna And Others Serve Finest Ethnic Style!
- 16 hrs ago From Alia Bhatt To Kriti Sanon, Korean Beauty Products That Bollywood Divas Swear By
- 19 hrs ago Exclusive: On World Malaria Day 2024, Dr Shares Danger Signs Parents Must Watch Out For In Child With Malaria
- 20 hrs ago Exclusive: Expert Debunks 5 Common Misconceptions About Expectant Mothers That You Need To Steer Clear From
Don't Miss
- Movies Pavi Caretaker Box Office Collection Day 1 Prediction: Dileep's Movie Expected To Open Strongly
- Sports Who Won Yesterday's IPL Match 41? SRH vs RCB, IPL 2024 on April 25: Royal Challengers Bangalore End Losing Streak
- Finance Bajaj Group Stock Declares Rs. 60/Share Dividend: Buy Ahead of Record Date On 28 June?
- News MEA Dismisses US Human Rights Report On Manipur As 'Biased And Misinformed'
- Automobiles Royal Enfield Unveils Revolutionary Rentals & Tours Service: Check Out All Details Here
- Technology Elon Musk’s X Is Launching a TV App Similar to YouTube for Watching Videos
- Education AICTE introduces career portal for 3 million students, offering fully-sponsored trip to Silicon Valley
- Travel Escape to Kalimpong, Gangtok, and Darjeeling with IRCTC's Tour Package; Check Itinerary
Drug That May Treat Serious COVID-19 Complication In Children Identified
Scientists have identified a promising drug candidate for the treatment of a rare but severe, and potentially life-threatening condition in children infected with the SARS-CoV-2 virus, that causes Covid-19.
Multi-inflammatory syndrome in children (MIS-C) usually develops weeks to months after children have experienced a mild or even asymptomatic case of Covid-19, the researchers said.MIS-C leads to high fevers and a hyperinflammatory response that can affect multiple organs, including the heart, brain and gastrointestinal organs, they said.
A previous study by researchers at Massachusetts General Hospital (MGH) and Brigham and Women's Hospital (BWH) in the US showed that in cases of MIS-C, the SARS-CoV-2 virus can remain in the gut for weeks to months after the infection.
When SARS-CoV-2 is present in the gut, an impaired mucosal barrier can allow small viral particles, such as the spike protein, to enter the bloodstream, leading to infections such as Covid-19 and in rare cases, the hyperinflammatory response that triggers MIS-C.
The SARS-CoV-2 virus uses the spike protein to enter and infect the cells.
"Working collaboratively, we have been able to demonstrate that viral particles that remain in the gut long after Covid-19 infection can instigate MIS-C," said David Walt, senior author of the study published in the journal Critical Care Explorations."Building on this important discovery, we wanted to see if treatment with a drug developed for another condition -- celiac disease -- could help resolve symptoms in children experiencing MIS-C," said Walt.
The team administered the drug larazotide acetate to four extremely ill children ages 3 to 17 being treated for MIS-C.
The study shows that larazotide decreases the release of zonulin, a molecule that can lead to increased gut permeability and an impaired mucosal barrier, a layer of thick mucus in the gut.
The researchers compared the clinical outcomes of the four children who received larazotide plus steroids and intravenous immune globulin (IVIG) to 22 children who received only steroids and IVIG.The children who received four daily oral doses of larazotide acetate had a significantly faster resolution of gastrointestinal symptoms and a slightly shorter hospital stay, they said.The study also found that serum levels of the spike protein dropped much more quickly in children treated with larazotide, clearing from the blood within one day, versus 10 days for children not treated with the drug."These findings suggest that larazotide may provide a safe and beneficial adjuvant therapy for the treatment of MIS-C," the researchers said."Expansion of clinical trials is urgently needed to ascertain the clinical impact of larazotide on MIS-C," they added.
- wellnessCOVID-19: DGCI Grants Restricted Emergency-Use Nod To Corbevax Vaccine For 12-18 Age Group
- healthNo Clear Evidence Yet On Omicron's Transmissibility, Immune Evasion, Severity In India: INSACOG
- healthIndia's Omicron Count Crosses 160
- healthCOVID-19: India Adds Ghana And Tanzania To List Of 'At-Risk' Countries
- health1 In 3 Indians Continue To Refrain From Carrying Masks When Stepping Out: Survey
- healthCOVID-19: Govt Writes To States/UT Over Rising Weekly Positivity Rates And Deaths
- healthOmicron: Is It Too Soon To Panic About Existing COVID Vaccines And The New Variant?
- healthCovaxin Gets WHO Approval For Emergency Use Listing
- womenExclusive: The Pandemic and Girls' Education - 11 Million Girls May Never Go Back To School And Here's Why
- disorders cureIndia Reports First Five Cases Of Cytomegalovirus Related Rectal Bleeding In COVID-19 Patients
- disorders cureHow To Download COVID-19 Vaccination Certificate Online? Step-By-Step Guide
- disorders cureCOVID-19 Lambda Variant, A New ‘Variant Of Interest’, WHO: Everything You Need To Know